Esperite (ESP.AS) Stock Price
Esperite Price
Over the last 13 years Esperite grew revenue by 7.6% annually, reaching 16.55 M EUR. Earnings per share have grown at 0.4% per year over the last 6 years. For Esperite, the net margin of -76.9% is down versus -11.8% a few years ago. The dividend has grown at 15.5% per year over the past 2 years.
Esperite stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Esperite over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Esperite stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Esperite's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Esperite Price |
|---|
Esperite Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Esperite Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM EUR |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM EUR |
| EBITM EUR |
| EBIT MARGIN% |
| NET INCOMEM EUR |
| NET INCOME GROWTH% |
| SHARESM |
| 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.00 | 8.00 | 10.00 | 17.00 | 29.00 | 38.00 | 40.00 | 41.00 | 36.00 | 29.00 | 27.00 | 27.00 | 26.00 | 16.00 |
| – | 33.33 | 25.00 | 70.00 | 70.59 | 31.03 | 5.26 | 2.50 | -12.20 | -19.44 | -6.90 | – | -3.70 | -38.46 |
| 66.67 | 62.50 | 60.00 | 64.71 | 68.97 | 71.05 | 67.50 | 65.85 | 63.89 | 65.52 | 62.96 | 51.85 | 53.85 | 62.50 |
| 4.00 | 5.00 | 6.00 | 11.00 | 20.00 | 27.00 | 27.00 | 27.00 | 23.00 | 19.00 | 17.00 | 14.00 | 14.00 | 10.00 |
| – | 2.00 | 2.00 | 5.00 | 2.00 | 4.00 | 4.00 | 2.00 | -1.00 | – | -3.00 | -7.00 | -5.00 | -7.00 |
| – | 25.00 | 20.00 | 29.41 | 6.90 | 10.53 | 10.00 | 4.88 | -2.78 | – | -11.11 | -25.93 | -19.23 | -43.75 |
| – | 2.00 | 2.00 | 3.00 | 2.00 | 1.00 | 2.00 | 2.00 | -17.00 | -3.00 | -5.00 | -7.00 | -8.00 | -12.00 |
| – | – | – | 50.00 | -33.33 | -50.00 | 100.00 | – | -950.00 | -82.35 | 66.67 | 40.00 | 14.29 | 50.00 |
| 9.64 | 9.64 | 9.64 | 7.53 | 9.39 | 9.24 | 9.27 | 9.30 | 9.34 | 9.26 | 9.73 | 10.03 | 10.36 | 13.70 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Esperite generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Esperite retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Esperite's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Esperite has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Esperite's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Esperite stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Esperite Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Esperite business model & stock analysis
Esperite SWOT Analysis
Strengths
- Strong intellectual property portfolio with innovative technologies
- Established brand recognition and reputation in the industry
- Diversified product portfolio catering to various market segments
- Strong relationships with key partners and suppliers
- Experienced and knowledgeable management team
- Solid financial performance and stable revenue growth
Weaknesses
- Dependent on a limited number of key customers
- Vulnerable to changes in regulatory environment affecting the industry
- Limited geographical presence and market penetration
- Relatively high production costs affecting profit margins
- Limited diversification within certain product lines
Opportunities
- Growing demand for innovative healthcare technologies
- Expansion into emerging markets with increasing healthcare investments
- Partnerships and collaborations for research and development
- Acquisition or licensing of complementary technologies or products
- Increasing trend towards personalized medicine and genetic testing
Threats
- Intense competition from established and emerging players
- Economic and political instability affecting market dynamics
- Stringent regulations and compliance requirements in the healthcare industry
- Rapid technological advancements and potential disruptive innovations
- Potential entry of new competitors with disruptive business models
Esperite Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Esperite historical P/E ratio, EBIT multiple, and P/S ratio
Esperite annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Esperite shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Esperite Dividend History
3 years of dividend payments · 2 consecutive increases
Esperite dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Esperite shareholder structure
| % | Name |
|---|---|
11.42928% |
Esperite Executives and Management Board
6 members · avg. age 63 · 33 % women
Management
Evi Mattil
Acting Chief Executive Officer, Chief Commercial Officer
Mr. Hugo Brugiere
Chief Executive Officer, Director · since 2020
Board of Directors
Dr. Karin Dorrepaal (59)
Non-Executive Director
Walter van Pottelberge (69)
Chairman of the Board · since 2007
Mr. Frederic Amar
Director · since 2014
Dr. Ronald Lorijn (62)
Non-Executive Director
Esperite Supply Chain
Frequently asked questions about Esperite
The business model of Esperite NV focuses on offering innovative solutions in the field of biotechnology, particularly in the area of stem cells. Esperite NV, a company based in the Netherlands, is dedicated to the development and commercialization of advanced therapies for regenerative medicine, cellular therapy, and personalized medicine. This includes the collection, processing, storage, and distribution of stem cells from multiple sources, such as umbilical cord blood and tissue. By leveraging their expertise and partnerships, Esperite NV aims to provide valuable medical services and products that contribute to improving patient outcomes and healthcare advancements.
Esperite NV is primarily active in the healthcare industry.
Esperite NV faces competition from several companies in the market. Some of its main competitors include Cryo-Save Group, StemCare, and FamilyCord. These companies also operate in the field of stem cell banking and offer similar services. However, Esperite NV distinguishes itself through its innovative technology and extensive global presence. It strives to maintain a competitive edge by continuously advancing its product offerings and expanding its customer base.
Esperite NV is a company with a rich history and background. Established in 2000, Esperite NV, formerly known as Cryo-Save Group NV, is a leading biotech company specializing in the collection, processing, and storage of stem cells obtained from umbilical cord blood and tissue. The company has an extensive global presence, operating multiple cryopreservation and processing laboratories across Europe and South Africa. Through its subsidiary, Cryo-Save, Esperite NV has successfully stored over 325,000 samples, providing families with a valuable resource for future medical treatments. With a strong commitment to research and innovation, Esperite NV continues to contribute significantly to the advancement of regenerative medicine and stem cell-based therapies.
Esperite NV, a renowned company in the stock market, has achieved several significant milestones. Over the years, Esperite NV has successfully expanded its global presence, establishing a strong foothold in the field of cell therapy and biobanking. With strategic partnerships and collaborations with industry leaders, Esperite NV has propelled innovation and advancements in stem cell research. Additionally, the company has consistently delivered breakthrough technologies, contributing to the development of groundbreaking medical solutions. Esperite NV's commitment to excellence and dedication to its stakeholders have led to consistent growth and enhanced shareholder value, making it a leading player in the stock market.
Esperite NV, a renowned company in the stock market, primarily operates in various countries and regions. It has a significant presence in the European market, with a focus on countries such as the Netherlands, Spain, Belgium, and the United Kingdom. Additionally, Esperite NV extends its reach to key regions including the Middle East and North Africa. With its diversified portfolio and strategic partnerships, Esperite NV has established a strong foothold in these regions, allowing it to cater to a wide range of investors and stakeholders.
Esperite NV represents values of innovation, scientific excellence, and commitment to improving healthcare solutions. With a strong corporate philosophy centered around pioneering stem cell technologies, Esperite NV is dedicated to unlocking the therapeutic potential of stem cells for regenerative medicine. By leveraging its extensive expertise in cryopreservation and biomedical services, the company aims to empower patients and healthcare professionals with state-of-the-art tools for personalized medicine. Esperite NV's commitment to quality, safety, and ethical practices resonates throughout its operations, ensuring the utmost integrity in delivering advanced healthcare solutions.
The Esperite share (ESP.AS) is listed on 3 stock exchanges, including: London (0OMG.L).
Esperite NV is a Dutch company specializing in life sciences. It operates a diversified business model consisting of various divisions to achieve its goals in research and development and the provision of services to the medical industry. The company's primary division is the biological cell banking unit, operating under the brand name CryoSave. CryoSave collects stem cells from umbilical cord blood and tissue, dental pulp, milk teeth, adipose tissue, and other tissues with high healing potential. These stem cells are used in the treatment of diseases such as diabetes, cancer, neurological disorders, and other serious conditions. The company also operates the Progenity AB division, a biotech company specializing in the development and production of solutions for cell transfection and culture. Progenity AB also provides services for in vitro research, such as cell line development, cell culture provision, and management. Esperite NV also operates the DNA amplification division, operating under the brand name LifeCode. LifeCode is a leading provider of DNA amplification solutions for the forensic, medical, and scientific community. LifeCode's solutions include reagents and instruments for polymerase chain reaction (PCR) and other amplification and sequencing technologies. Additionally, the company is also involved in the field of animal health, particularly in cattle breeding. Esperite NV's animal health division operates under the name Cryo-Save Agro, providing leading services in cattle semen and genetic advisory services to breeders. In addition to its businesses in biological research and development, Esperite NV is also involved in clinical trials. The company provides services for the planning of clinical trials, development of protocols, and data management for studies. Esperite NV also operates a charity organization, the Cord for Life Foundation, which functions as a nonprofit organization collecting funds for charitable purposes to support stem cell research and development and promote public awareness of the benefits of stem cell therapies. In summary, Esperite NV operates a diverse business model focusing on the research and development of biological solutions and services. With its divisions in biological cell banking, cell transfection and culture, DNA amplification, animal health, and clinical trials, the company offers a wide range of products and services to its customers, contributing to the advancement of science in the field of regenerative medicine and driving progress in the medical industry.
The revenue cannot currently be calculated for Esperite.
The profit cannot currently be calculated for Esperite.
The P/E ratio cannot be calculated for Esperite at the moment.
The P/S cannot be calculated for Esperite currently.
The Eulerpool Quality Score for Esperite is 1/10.
The ISIN of Esperite is NL0009272137. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Esperite is ESP.AS. The ticker symbol is used to trade Esperite shares on the stock exchange.
The current dividend yield of Esperite is - %.
Esperite is assigned to the 'Health' sector.
The dividends of Esperite are distributed in EUR.
Esperite stock
Esperite Peer Group
Esperite Ticker
Esperite FIGI
All fundamentals and in-depth analysis of Esperite
Our stock analysis for Esperite stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Esperite. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.